Design and characterization of lipid nanocarriers for oral delivery of immunotherapeutic peptides

The use of therapeutic proteins and peptides is of great interest for the treatment of many diseases, and advances in nanotechnology offer a path toward their stable delivery via preferred routes of administration. In this study, we sought to design and formulate a nanostructured lipid carrier (NLC)...

Full description

Saved in:
Bibliographic Details
Published in:Journal of biomedical materials research. Part A 2023-07, Vol.111 (7), p.938-949
Main Authors: Calderón‐Colón, Xiomara, Zhang, Yichuan, Tiburzi, Olivia, Wang, Jialu, Hou, Shenda, Raimondi, Giorgio, Patrone, Julia
Format: Article
Language:English
Subjects:
Administration, Oral
Antigens
Autoimmune diseases
Design
Drug Carriers - chemistry
Immune system
Immunotherapy
Insulin
insulin peptide
Latent heat
lipid nanoparticle
Lipids
Lipids - chemistry
Lymph nodes
lymphoid tissues
Melting
Melting point
Melting points
Nanostructures - chemistry
Nanotechnology
Oral administration
oral delivery
Particle Size
Peptides
Polydispersity
Statistical methods
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The use of therapeutic proteins and peptides is of great interest for the treatment of many diseases, and advances in nanotechnology offer a path toward their stable delivery via preferred routes of administration. In this study, we sought to design and formulate a nanostructured lipid carrier (NLC) containing a nominal antigen (insulin peptide) for oral delivery. We utilized the design of experiments (DOE) statistical method to determine the dependencies of formulation variables on physicochemical particle characteristics including particle size, polydispersity (PDI), melting point, and latent heat of melting. The particles were determined to be non‐toxic in vitro, readily taken up by primary immune cells, and found to accumulate in regional lymph nodes following oral administration. We believe that this platform technology could be broadly useful for the treatment of autoimmune diseases by supporting the development of oral delivery‐based antigen specific immunotherapies.
ISSN:1549-3296
1552-4965
DOI:10.1002/jbm.a.37477